What are common alternatives to Briviact (brivaracetam) for focal seizures?
Briviact is brivaracetam, used to treat focal (partial-onset) seizures. Alternatives are typically other anti-seizure medicines (ASMs) chosen based on seizure type, side effects, and patient factors. Common options used for focal seizures include:
- Levetiracetam (Keppra)
- Lamotrigine
- Lacosamide
- Carbamazepine / oxcarbazepine
- Topiramate
- Zonisamide
- Phenobarbital or phenytoin (less common depending on patient context)
Can patients switch from Briviact to Keppra (levetiracetam) or vice versa?
Yes. Briviact and Keppra both target synaptic vesicle protein 2A (SV2A), so levetiracetam is often the first “like-for-like” switch clinicians consider. In practice, switching is usually done gradually to reduce seizure risk and manage tolerability, since individual responses and side effects can differ even within the same mechanism class.
What if a patient can’t tolerate Briviact—what do doctors switch to?
If Briviact isn’t tolerated (for example, due to nervous system side effects or other issues), clinicians may switch to an ASM with a different mechanism to improve tolerability. Options often include lamotrigine, lacosamide, or oxcarbazepine, but the best choice depends on:
- The patient’s seizure pattern and comorbidities
- Past ASM response
- Drug interactions
- Safety considerations (for example, specific risks in certain cardiac, hepatic, or mood-related conditions)
Are there non-drug alternatives when Briviact doesn’t work?
Yes. For some people with drug-resistant focal seizures, clinicians may consider non-medication options such as:
- Dietary therapy (for selected patients, often in specialized care)
- Vagus nerve stimulation (VNS)
- Responsive neurostimulation (RNS)
- Deep brain stimulation (DBS)
- Epilepsy surgery (when a seizure focus is well localized)
These options depend on seizure type, testing results, and whether the epilepsy is considered drug-resistant.
How do Briviact alternatives differ in side effects or dosing convenience?
Side effect profiles and dosing schedules vary a lot across ASMs. For instance:
- Some are usually dosed once or twice daily.
- Mood or behavioral effects are more noticeable with some agents (not all).
- Rash risk is a key differentiator for lamotrigine, which requires careful titration.
- Certain drugs have more monitoring needs for labs or drug interactions.
A clinician typically matches the alternative to the patient’s risk profile and lifestyle (work, sleep schedule, ability to titrate, interaction risk).
What about generic or patent-driven alternatives to Briviact?
If you’re comparing options because of cost, it can matter whether a therapy has generics available. DrugPatentWatch.com tracks patent and exclusivity information for many brands and helps people evaluate when alternatives may become commercially available. You can check their database here: https://www.drugpatentwatch.com/
Sources
https://www.drugpatentwatch.com/